Peter Klein - Denali Therapeutics Independent Director
| DNLI Stock | USD 15.56 0.55 3.41% |
Director
Mr. Peter S. Klein is Independent Director of the Company. Mr. Klein has 25 years of experience as a senior finance executive. He served as Chief Financial Officer of Microsoft Corporation from November 2009 until May 2013 and spent over 11 years at Microsoft. Most recently, he served as Chief Financial Officer of WME, a global leader in sports and entertainment marketing, from January 2014 until June 2014 since 2018.
| Age | 55 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650-866-8548 |
| Web | https://www.denalitherapeutics.com |
Denali Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0941) % which means that it has lost $0.0941 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1401) %, meaning that it created substantial loss on money invested by shareholders. Denali Therapeutics' management efficiency ratios could be used to measure how well Denali Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.13. The current Return On Capital Employed is estimated to decrease to -0.19. As of now, Denali Therapeutics' Asset Turnover is decreasing as compared to previous years.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Rafale Tordjman | Ascendis Pharma AS | 44 | |
| JingShyh Su | BeiGene | 65 | |
| Thomas Malley | BeiGene | 49 | |
| Robert Goldberg | Cerevel Therapeutics Holdings | 69 | |
| Jonathan Silverstein | Ascendis Pharma AS | 49 | |
| Lonnel Coats | Blueprint Medicines Corp | 53 | |
| Lynn Seely | Blueprint Medicines Corp | 59 | |
| Nicholas Lydon | Blueprint Medicines Corp | 61 | |
| Charles Rowland | Blueprint Medicines Corp | 59 | |
| Michael Goller | BeiGene | 42 | |
| Richard Flavell | Cerevel Therapeutics Holdings | 71 | |
| Stephanie OBrien | Apellis Pharmaceuticals | 59 | |
| Ranjeev Krishana | BeiGene | 43 | |
| Ke Tang | BeiGene | 34 | |
| George Demetri | Blueprint Medicines Corp | 61 | |
| Qingqing Yi | BeiGene | 45 | |
| Timothy Chen | BeiGene | 60 | |
| Donald Glazer | BeiGene | 72 | |
| Aflalo Guimaraes | Cerevel Therapeutics Holdings | 45 | |
| Albert Cha | Ascendis Pharma AS | 45 | |
| Cheryl Morley | Cerevel Therapeutics Holdings | 59 | |
Management Performance
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0941 |
Denali Therapeutics Leadership Team
Elected by the shareholders, the Denali Therapeutics' board of directors comprises two types of representatives: Denali Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Denali. The board's role is to monitor Denali Therapeutics' management team and ensure that shareholders' interests are well served. Denali Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Denali Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carole MD, Chief Development | ||
| Peter Klein, Independent Director | ||
| Douglas Cole, Independent Director | ||
| Ryan Watts, President CEO, Co-Founder, Director | ||
| Steve Krognes, Treasurer Director | ||
| Dana Andersen, CTO and Manufacturing Officer | ||
| Jennifer Cook, Independent Director | ||
| Tyler Nielsen, Senior Finance | ||
| Cindy Dunkle, Chief Officer | ||
| Joe Lewcock, Chief Officer | ||
| Alexander Schuth, Co-Founder, COO, Head of Corporate Development | ||
| Carole Ho, Chief Medical Officer | ||
| Vicki Sato, Independent Director | ||
| Peter Chin, Senior Affairs | ||
| Marc TessierLavignec, Chairman of the Board, Co-Founder | ||
| Mark Rowen, Vice Development | ||
| David Schenkein, Independent Director | ||
| Chris Walsh, General Counsel | ||
| Robert Nelsen, Independent Director | ||
| Jay Flatley, Director | ||
| Laura Hansen, Vice Relations | ||
| Alexander MD, CFO, CoFounder | ||
| Marc TessierLavigne, Chairman CoFounder | ||
| Tony Estrada, Senior Sciences | ||
| Katie Peng, Chief Officer |
Denali Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Denali Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0941 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 1.24 B | ||||
| Shares Outstanding | 142.54 M | ||||
| Shares Owned By Insiders | 13.77 % | ||||
| Shares Owned By Institutions | 79.49 % | ||||
| Number Of Shares Shorted | 9.41 M | ||||
| Price To Earning | 60.91 X |
Pair Trading with Denali Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Denali Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Denali Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Denali Stock
| 0.75 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.68 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.64 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Denali Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Denali Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Denali Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Denali Therapeutics to buy it.
The correlation of Denali Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Denali Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Denali Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Denali Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets |
Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.06) | Revenue Per Share 2.406 | Quarterly Revenue Growth (1.00) | Return On Assets (0.09) | Return On Equity (0.14) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.